ArticleACS omega2026
Design, Synthesis, Molecular Docking, Dynamics Simulation, and Biological Evaluation of Novel Thiazolidinedione Derivatives Against Breast Cancer with Apoptosis-Inducing Activity.
Article in ACS omega, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Breast cancer remains one of the leading causes of cancer-related deaths among women worldwide. The chemotherapeutic drugs used in treatment often have serious side effects. In light of their anticancer potential, thiazolidinedione (TZD) derivatives are considered to be promising candidates for the development of novel antitumor agents. The objective of this study is to synthesize and produce two sets of TZD derivatives by combining the structural features of microtubule-targeting drugs used in breast cancer treatment, and to determine their molecular docking, molecular dynamics simulations, ADMET profile, antiproliferative, and apoptotic effect potential. In the present study, PZ-11 was determined by xCELLigence analysis to have the highest antiproliferative potential among all compounds tested on MCF-7 breast cancer cells. The cytotoxic activity of the synthesized compounds was evaluated against MCF-7 breast cancer cells, revealing IC
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.